



Innovative back microsurgery

Press release

VEXIM Announces the First Sales of its Masterflow™ Injection System in the United States

15 surgeries successfully performed at Oklahoma Spine Hospital

Dr. Douglas Beall appointed to the Board of Directors

Toulouse, February 2, 2015 - VEXIM (FR0011072602 - ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announced the success of 15 surgeries carried out with the Masterflow™ Injection System at Oklahoma Spine Hospital (Oklahoma City, Oklahoma, USA), one of the preeminent American hospitals specializing in spine surgery. With this success, VEXIM marks the effective launch of its broader sales & marketing activities in the United States, reflecting a quick ramp-up of VEXIM Inc., VEXIM's wholly-owned US subsidiary set up in September 2014, responsible for commercializing the company's products through a comprehensive network of carefully-selected spine-specialist agents.

The first surgeries were carried out last December, i.e. just days after the system's FDA registration (see press release of December 10, 2014).

Dr. Douglas Beall, interventional radiologist affiliated with Oklahoma Spine Hospital, comments: *"We are delighted to have been among the first to use this innovative system for mixing and injecting orthopedic cement, and we are very pleased with the outcome. From the cement's preparation through to the end of the operation, this system has proved to be easy to use, safe and extremely precise regarding the injection itself, thus allowing us to rapidly reduce and stabilize the fracture. He adds: "After these first Masterflow™ injections, I strongly feel that it is the best performing vertebral augmentation system I've used in the past 10 years."*

Following these initial interventions by Dr. Douglas Beall, and given his in-depth knowledge of the American spine market, VEXIM has decided to offer him a position on the Board of Directors. He will thus contribute to educating the medical community about VEXIM's technologies and products and supporting the Company's development in the United States. His appointment will be submitted to the next AGM for approval.

Vincent Gardès, CEO of VEXIM, concludes: *"We had been eagerly awaiting feedback from U.S. doctors regarding our Masterflow™ Injection System, as we knew the satisfaction of both patients and physicians were crucial for the system's success. We are delighted, but not surprised, that these surgeries have gone smoothly and that the response from physicians indicates a strong desire to use this system to treat their patients. The adoption of this product by surgeons and interventional radiologists is pivotal to our development strategy in the U.S., which is the world's largest spine trauma market. We are, therefore, highly confident in the success of our ramp-up on this market in 2015 and will further improve our future US commercial strategy in accordance with market feedback. The Masterflow™ system is also expected to become available in Europe during the first half of this year."*

He adds: “Furthermore, we are delighted to welcome Dr. Douglas Beall to our Board of Directors. His experience will be a valuable asset for VEXIM’s strategic orientations in the United States.”



About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from Bpifrance public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors in Argentina, Taiwan, Belgium, South Africa, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil. VEXIM has been listed on Alternext Paris since May 2012.

For further information, please visit www.vexim.com

SpineJack®¹ implant for treating Vertebral Compression Fractures

An important advantage of SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Specialized instruments, guided by X-ray, allow the implants into the vertebra to be carried out by minimally-invasive surgery in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of three titanium implants with three different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029. SpineJack® is an investigational device in the United States and is not available for U.S. sale.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

shareholders@vexim.com

NewCap

Investor Relations /

Strategic Communications

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol /

Sophie Colin

vexim@alizerp.com

Tel: +33 1 44 54 36 66 /

+33 6 64 18 99 59

LifeSci Advisors LLC

Investor Relations

Michael Wood

www.lifesciadvisors.com

+1 646 597 6983



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM
- **Member of the EnterNext© PEA-PME 150 index**



¹ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.